Glucose Monitoring Global Market – Forecast to 2025

Publishing Date : June, 2019
Report Code : HCMD0148
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Glucose Monitoring consists of products that are essential for patients suffering from diabetes. With the projected rise in the aged population and awareness about such conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the Glucose Monitoring global market is expected to grow at CAGR of XX% reach $12,897.0 million by 2025. Factors driving the Glucose Monitoring market are a global rise in the prevalence and incidence of diabetes, continuous technological advancement, increasing demand for less invasive products, and an increase in R&D investments are driving the market growth. Increase in obesity population due to lifestyle changes, increase in urbanization, untapped markets like the Middle East, Africa shows that glucose monitoring market has vast opportunities in the coming years. Frequent product recalls i.e. glucose testing strips due to manufacturing defects or supply of expired test strips and less product differentiation among the self blood glucose monitors are the factors that are restraining the market growth. The limited reimbursement facilities and alternative treatments that include cell-based assays, biomarkers identification and artificial pancreas and high cost associated with Continuous Glucose Monitoring (CGM) are threats for the market growth.

Glucose Monitoring global market is classified based on products, sample type, end-users and geography. The products segment is divided into three segments i.e., Invasive, Non-Invasive and lab-based glucose monitoring products. The Invasive glucose monitoring products segment accounted the largest share in 2018 and is projected to grow at a low single digit CAGR from 2018 to 2025 due to technological advancements, easy use, patient-friendly, etc. Invasive products are classified into Self glucose monitoring and continuous glucose products. The self glucose monitoring segment accounted for the largest share in 2018 due to the development of minimally invasive products. The Self glucose monitoring products are further classified into blood glucose monitors, blood glucose test strips, lancets and others. The blood glucose testing strips segment accounted for the largest share in 2018 due development of no coding strips. The continuous glucose monitoring market includes sensors/receiver and transmitter. The continuous glucose market includes products sensors/receiver and transmitter. Continuous glucose segment is the fastest growing segment and is projected to grow at a strong double digit CAGR from 2018 to 2025.

Based on sample type the market is segmented into blood, urine and others. The blood segment accounted for the largest share in 2018 due to the accuracy of results. Other source based glucose monitoring segment is fastest growing segment and is projected to grow exponentially from 2018 to 2025 due to increases R&D investment, many products is CE approved and expected launch very soon in the market.

Based on end users the market is segmented into hospitals, private clinics, home care and ambulatory settings. Among end-users, home care segment accounted for the largest share in 2018 and is projected to grow at a low single digit CAGR from 2018 to 2025 due to the availability of over the counter (OTC) self blood glucose monitor and ease in operating these monitors and thereby reducing the frequent visits to hospitals or clinics for checking glucose levels.

Based on geography the market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Others), Asia-Pacific (Japan, China, India and Others) and Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the highest market share followed by Europe. The steep rise in aging population, advancement in technology, awareness of people about treatment options and favorable government policies are driving factors of glucose monitoring market. However, Asian countries especially India and China are the fastest growing regions with its growing demand for glucose monitoring products.

Major players in Glucose monitoring market include Abbott Laboratories (U.S.), Roche (Switzerland), LifeScan (U.S.), Dexcom (U.S.), Medtronic, Inc. (Ireland), Ascensia (Switzerland), Arkray (Japan), Sinocare (China), B. Braun Melsungen AG (Germany), Bio-Rad (U.S.),  etc.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

• North America

o U.S.

o Rest of North America

• Europe

o Germany

o Italy

o France

o Rest of EU

• Asia-Pacific

o Japan

o China

o India

o Rest of APAC

• Rest of the World (RoW)

o Brazil

o Rest of Latin America

o Middle-East (Middle East & Others)

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     The global rise in the prevalence and incidence of diabetes
        • 3.3.1.2     Technological advancements in glucose monitoring devices
        • 3.3.1.3     Increasing demand for less invasive devices or point of care
        • 3.3.1.4     Increasing r & d investments
      • 3.3.2     RESTRAINS AND THREATS
        • 3.3.2.1     Availability of alternative treatment
        • 3.3.2.2     High cost associated with the products
        • 3.3.2.3     Inadequate reimbursement
        • 3.3.2.4     Product recalls
        • 3.3.2.5     Strict regulation of glucose monitoring devices by regulatory organizations like the fda and others
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     INDIA
      • 3.4.5     JAPAN
    • 3.5     REIMBURSEMENT SCENARIO
    • 3.6     PATENT ANALYSIS
    • 3.7     TECHNOLOGY ADVANCEMENTS
      • 3.7.1     ARTIFICIAL INTELLIGENCE AND RADAR TECHNOLOGY
      • 3.7.2     NON-INVASIVE CONTINUOUS GLUCOSE MONITORING WEARABLE
      • 3.7.3     TEAR GLUCOSE MONITORING TECHNOLOGY
      • 3.7.4     SALIVA BASED BIOSENSORS
      • 3.7.5     MICRONEEDLE PATCH
      • 3.7.6     PHOTOTHERMAL DETECTION OF GLUCOSE LEVELS
    • 3.8     PRODUCT LAUNCHES AND APPROVALS
    • 3.9     FUNDING SCENARIO
    • 3.1     GLUCOSE MONITORING - DEALS
    • 3.11     CLINICAL TRIAL DATA
    • 3.12     PORTER’S FIVE FORCE ANALYSIS
      • 3.12.1     THREAT OF NEW ENTRANTS
      • 3.12.2     THREAT OF SUBSTITUTES
      • 3.12.3     BARGAINING POWER OF SUPPLIERS
      • 3.12.4     BARGAINING POWER OF BUYERS
      • 3.12.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.13     SUPPLY CHAIN ANALYSIS
    • 3.14     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.14.1     GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
      • 3.14.2     SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE
      • 3.14.3     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET
  • 4     GLUCOSE MONITORING GLOBAL MARKET, BY PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     INVASIVE GLUCOSE MONITORING
      • 4.2.1     SELF GLUCOSE MONITORING
        • 4.2.1.1     Blood glucose meter
        • 4.2.1.2     Blood glucose testing strips
        • 4.2.1.3     Lancets
        • 4.2.1.4     Others
      • 4.2.2     CONTINUOUS GLUCOSE MONITORING
        • 4.2.2.1     Glucose Sensors
        • 4.2.2.2     Transmitters and Receivers
    • 4.3     NON-INVASIVE GLUCOSE MONITORING
    • 4.4     LAB BASED GLUCOSE MONITORING
  • 5     GLUCOSE MONITORING GLOBAL MARKET, BY SAMPLE SOURCE
    • 5.1     INTRODUCTION
    • 5.2     BLOOD-BASED GLUCOSE MONITORING
    • 5.3     URINE BASED GLUCOSE MONITORING
    • 5.4     OTHER SOURCES BASED GLUCOSE MONITORING
  • 6     GLUCOSE MONITORING GLOBAL MARKET, BY END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS
    • 6.3     HOME CARE
    • 6.4     PRIVATE CLINICS
    • 6.5     AMBULATORY SETTINGS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     ITALY
      • 7.3.3     FRANCE
      • 7.3.4     REST OF EUROPE
    • 7.4     ASIA - PACIFIC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF ASIA-PACIFIC
    • 7.5     REST OF THE WORLD
      • 7.5.1     BRAZIL
      • 7.5.2     MIDDLE EAST & OTHERS
      • 7.5.3     REST OF LATIN AMERICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     NEW PRODUCT LAUNCHES
    • 8.3     COLLABORATION & PARTNERSHIPS
    • 8.4     OTHER DEVELOPMENTS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES, INC
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     ARKRAY, INC.
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     ASCENSIA DIABETES CARE HOLDINGS AG.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     B.BRAUN MELSUNGEN AG
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     BIO-RAD LABORATORIES
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     DEXCOM, INC.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     LIFESCAN (JOHNSON & JOHNSON)
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MEDTRONIC, PLC
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     SINOCARE INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.1     ROCHE HOLDINGS AG
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • TABLE 2     GLUCOSE MONITORING DEVICES GLOBAL MARKET REVENUE, BY PRODUCTS, (2017-2025) ($MN)
      • TABLE 3     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 4     INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2017-2025) ($MN)
      • TABLE 5     SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2017-2025) ($MN)
      • TABLE 6     SELF MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 7     BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 8     BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 9     LANCETS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 10     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 11     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 12     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2017-2025) ($MN)
      • TABLE 13     GLUCOSE SENSORS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 14     TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 15     NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 16     LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 17     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY SAMPLE SOURCE, (2017-2025) ($MN)
      • TABLE 18     BLOOD-BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 19     URINE BASED GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 20     OTHER SOURCES BASED GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 21     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY END USER, (2017-2025) ($MN)
      • TABLE 22     HOSPITAL GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 23     HOME CARE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 24     PRIVATE CLINICS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 25     AMBULATORY SETTING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 26     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • TABLE 27     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 28     NORTH AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 29     NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 30     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 31     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2017-2025) ($MN)
      • TABLE 32     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2017-2025) ($MN)
      • TABLE 33     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2017-2025) ($MN)
      • TABLE 34     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 35     EUROPE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 36     EUROPE SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 37     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 38     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2017-2025) ($MN)
      • TABLE 39     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2017-2025) ($MN)
      • TABLE 40     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2017-2025) ($MN)
      • TABLE 41     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 42     ASIA-PACIFIC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 43     ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 44     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 45     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2017-2025) ($MN)
      • TABLE 46     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2017-2025) ($MN)
      • TABLE 47     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2017-2025) ($MN)
      • TABLE 48     ROW GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 49     ROW INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 50     ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 51     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • TABLE 52     ROW GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2017-2025) ($MN)
      • TABLE 53     ROW GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2017-2025) ($MN)
      • TABLE 54     ROW GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2017-2025) ($MN)
      • TABLE 55     NEW PRODUCT LAUNCHES (2018-2019)
      • TABLE 56     COLLABORATION & PARTNERSHIPS (2018-2019)
      • TABLE 57     OTHERS (2018-2019)
      • TABLE 58     ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 59     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 60     ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 61     B BRAUN MELSUNGEN: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 62     B BRAUN MELSUNGEN: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 63     B BRAUN MELSUNGEN: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 64     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 65     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 66     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 67     DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 68     DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 69     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 70     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 71     JOHNSON & JOHNSON: TOTAL REVENUE, BY MEDICAL DEVICES SEGMENTS, (2016-2018) ($MN)
      • TABLE 72     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 73     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 74     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 75     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 76     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 77     ROCHE HOLDINGS AG: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 78     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE, BY TYPES, (2016-2018) ($MN)
      • TABLE 79     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: GLUCOSE MONITORING GLOBAL MARKET
      • FIGURE 3     GLUCOSE MONITORING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     GLUCOSE MONITORING GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     GLUCOSE MONITORING GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     GLUCOSE MONITORING GLOBAL MARKET: PATENT FILING, BY MAJOR PLAYERS (2014-2019)
      • FIGURE 9     GLUCOSE MONITORING MARKET: PORTER’S ANALYSIS
      • FIGURE 10     GLUCOSE MONITORING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018
      • FIGURE 12     SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018
      • FIGURE 13     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018
      • FIGURE 14     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2018 V/S 2025) ($MN)
      • FIGURE 15     INVASIVE GLUCOSE MONITORING GLOBAL MARKET SHARE, BY PRODUCTS (2018 V/S 2025) (%)
      • FIGURE 16     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2018 V/S 2025) ($MN)
      • FIGURE 17     SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2018 V/S 2025) (%)
      • FIGURE 18     SELF GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 19     BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BY REGION (2018 V/S 2025) ($MN)
      • FIGURE 20     BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 21     LANCETS GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 22     OTHERS GLOBAL MARKET REVENUE, BY REGION (2018 V/S 2025) ($MN)
      • FIGURE 23     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 24     CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2018 V/S 2025) ($ MN)
      • FIGURE 25     GLUCOSE SENSORS GLOBAL MARKET SHARE, BY PRODUCTS (2018 V/S 2025) (%)
      • FIGURE 26     TRANSMITTER AND RECEIVER GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 27     NON-INVASIVE GLUCOSE MONITORS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 28     LAB BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 29     GLUCOSE MONITORING GLOBAL MARKET SHARE, BY SAMPLE SOURCE (2018 V/S 2025) (%)
      • FIGURE 30     BLOOD-BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 31     URINE BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 32     OTHER SOURCES BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018 V/S 2025) ($MN)
      • FIGURE 33     GLUCOSE MONITORING GLOBAL MARKET SHARE, BY END USER (2018 V/S 2025) (%)
      • FIGURE 34     HOSPITAL GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 35     HOME CARE GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 36     PRIVATE CLINICS GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 37     AMBULATORY SETTINGS GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 38     GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2017 - 2025) ($MN)
      • FIGURE 39     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018) ($MN)
      • FIGURE 40     NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2018 V/S 2025) (%)
      • FIGURE 41     NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • FIGURE 42     NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BY SAMPLE SOURCE (2018 V/S 2025) (%)
      • FIGURE 43     NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BY END-USER (2018) (%)
      • FIGURE 44     NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2018-2025) ($MN)
      • FIGURE 45     U.S. GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 VS 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 46     U.S. GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 47     REST OF NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCT, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 48     REST OF NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 49     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018) ($MN)
      • FIGURE 50     EUROPE SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2018 V/S 2025) (%)
      • FIGURE 51     EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • FIGURE 52     EUROPE GLUCOSE MONITORING MARKET SHARE, BY SAMPLE SOURCE (2018 V/S 2025) (%)
      • FIGURE 53     EUROPE GLUCOSE MONITORING MARKET SHARE, BY END-USER (2018) (%)
      • FIGURE 54     EUROPE GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2018 V/S 2025) ($MN)
      • FIGURE 55     GERMANY GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 56     GERMANY GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 57     ITALY GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 58     ITALY GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 59     FRANCE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 60     FRANCE GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 61     REST OF EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 62     REST OF EUROPE GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 63     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018) ($MN)
      • FIGURE 64     ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018 V/S 2025) ($MN)
      • FIGURE 65     ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • FIGURE 66     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 67     ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BY END-USER (2018) (%)
      • FIGURE 68     ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2018 V/S 2025) ($MN)
      • FIGURE 69     JAPAN GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 70     JAPAN GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 71     CHINA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 72     CHINA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 73     INDIA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 74     INDIA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 75     REST OF ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 76     REST OF ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 77     ROW GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2018) ($MN)
      • FIGURE 78     ROW SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2018 V/S 2025) (%)
      • FIGURE 79     ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2017-2025) ($MN)
      • FIGURE 80     ROW GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 81     ROW GLUCOSE MONITORING MARKET SHARE, BY END-USER (2018) (%)
      • FIGURE 82     ROW GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2018 V/S 2025) ($MN)
      • FIGURE 83     BRAZIL GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 84     BRAZIL GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 85     MIDDLE EAST & OTHERS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 86     MIDDLE EAST & OTHERS GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 87     REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, (2018 V/S 2025) ($MN), BY SAMPLE SOURCE (2018 V/S 2025) ($MN)
      • FIGURE 88     REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2018) ($MN)
      • FIGURE 89     KEY GROWTH STRATEGIES (2018–2019)
      • FIGURE 90     SWOT: ABBOTT LABORATORIES
      • FIGURE 91     SWOT: ARKRAY, INC
      • FIGURE 92     SWOT: ASCENSIA DIABETES CARE
      • FIGURE 93     SWOT: B BRAUN MELSUNGEN
      • FIGURE 94     SWOT: BIO-RAD LABORATORIES
      • FIGURE 95     SWOT: DEXCOM INC.
      • FIGURE 96     SWOT: LIFESCAN (JOHNSON & JOHNSON)
      • FIGURE 97     SWOT: MEDTRONIC, PLC
      • FIGURE 98     SWOT: SINOCARE
      • FIGURE 99     SWOT: ROCHE HOLDINGS AG

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBOTT LABORATORIES
      • 2     A&T CORPORATION
      • 3     ACON DIABETES CARE INTERNATIONAL
      • 4     ADALTIS
      • 5     AGAMATRIX INC
      • 6     ALLIANCE INTERNATIONAL
      • 7     ALLMEDICUS
      • 8     AMBROSIA SYSTEMS
      • 9     ANDON HEALTH CO LTD
      • 10     APEX BIOTECHNOLOGY CORP
      • 11     ARKRAY
      • 12     ASCENSIA DIABETES CARE
      • 13     B.BRAUN
      • 14     BECTON DICKINSON
      • 15     BEIJING YICHENG BIOELECTRONICS TECHNOLOGY CO., LTD.
      • 16     BEURER GMBH
      • 17     BIOCHEMICAL SYSTEMS INTERNATIONAL
      • 18     BIOLAND TECHNOLOGY
      • 19     BIONIME CORPORATION
      • 20     BIOPTIK TECHNOLOGY
      • 21     BIO-RAD LABORATORIES
      • 22     BIOTELEMETRY INC
      • 23     BIOTEST MEDICAL CORPORATION
      • 24     BODYTEL GMBH
      • 25     BREMED LIMITED
      • 26     CAMBRIDGE SENSORS
      • 27     CAREMATIX INC
      • 28     CERAGEM MEDISYS INC.
      • 29     CHUNGDO PHARM. CO., LTD
      • 30     CONTEC MEDICAL SYSTEMS
      • 31     CONVERGENT TECHNOLOGIES
      • 32     DANAHER
      • 33     DARIO
      • 34     DELBIO INCORPORATION
      • 35     DEXCOM, INC
      • 36     DIABETOMICS, INC
      • 37     DIAMONTECH
      • 38     ECHO THERAPEUTICS
      • 39     EKF DIAGNOSTICS
      • 40     EMSIG GMBH CO
      • 41     ENTRA HEALTH SYSTEMS LLC
      • 42     EPS BIO TECHNOLOGY CORP.
      • 43     ERBA DIAGNOSTICS
      • 44     ESER DIGITAL
      • 45     EVIA MEDICLE TECHNOLOGIES
      • 46     FIA BIOMED GMBH
      • 47     FORA CARE, INC
      • 48     GE
      • 49     GENERAL LIFE BIOTECHNOLOGY
      • 50     GENESIS HEALTH TECHNOLOGIES
      • 51     GLOOKO
      • 52     GLUCO RX
      • 53     GLUCOSTRATUS LTD
      • 54     GLYSENS INCORPORATED
      • 55     GLYSURE LIMITED
      • 56     HANGZHOU SEJOY ELECTRONICS & INSTRUMENTS
      • 57     HEMOCUE AB
      • 58     HMD BIOMEDICAL
      • 59     HUBDIC CO LTD
      • 60     HYGEIA, INC.
      • 61     IDEAL LIFE INC.
      • 62     IHEALTH LABS INC
      • 63     IME-DC GMBH
      • 64     IN4 TECHNOLOGY CORP
      • 65     INFOPIA CO LTD
      • 66     INSIDE BIOMETRICS
      • 67     INSULET CORPORATION
      • 68     INTEGRITY APPLICATIONS
      • 69     INTERNATIONAL BIOMEDICAL
      • 70     INTUITY MEDICAL, INC
      • 71     I-SENS
      • 72     IXENSOR COMPANY LTD.
      • 73     JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD
      • 74     K-JUMP HEALTH CO., LTD
      • 75     LIFE PLUS
      • 76     LIFOTRONIC
      • 77     LIGHT TOUCH MEDICAL INC
      • 78     LOBECK MEDICAL AG
      • 79     L-TAC MEDICARE
      • 80     MEDISANA
      • 81     MEDIWISE
      • 82     MEDTRONIC PLC
      • 83     MENARINI GROUP
      • 84     MICO NANOBIOSYS LTD
      • 85     NATIONAL DIAGNOSTIC PRODUCTS
      • 86     NEMAURA MEDICAL INC
      • 87     NIPRO
      • 88     NOVA BIOMEDICAL
      • 89     NOVIOSENSE
      • 90     OK BIOTECH CO. , LTD
      • 91     OMRON HEALTHCARE
      • 92     OSANG HEALTH CARE CO LTD
      • 93     PALMDOC
      • 94     PENDIQ
      • 95     PEPEX BIOMEDICAL
      • 96     PHARMA TECH SOLUTIONS INC
      • 97     PHILOSYS INC
      • 98     PLATINUM EQUITY (LIFE SCAN INC)
      • 99     PREDIKTOR MEDICAL
      • 100     PRODIGY DIABETES CARE, LLC
      • 101     ROCHE DIAGONSTICS
      • 102     ROMED HOLLAND
      • 103     SANOFI
      • 104     SD BIOSENSOR
      • 105     SENSEONICS
      • 106     SINOCARE
      • 107     SORRENTO BIOCHEMICAL, INC.
      • 108     STAIRWAY LABORATORIES INC
      • 109     SYN-KIT, INC.
      • 110     TAIDOC TECHNOLOGY CORPORATION
      • 111     TANDOM DIABETES CARE
      • 112     TERUMO
      • 113     THERMO FISHER SCIENTIFIC
      • 114     TIANJIN EMPECS MEDICAL DEVICE CO., LTD.
      • 115     TOSOH CORPORATION
      • 116     TRINITY BIOTECH
      • 117     TRULY INSTRUMENT LIMITED
      • 118     TYSON BIORESEARCH INC
      • 119     VISGENEER INC
      • 120     VIVACHEK LABORATORIES, INC.